Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 9, 1996, Pages 1163-1169

  Cushman, Mary ^a,b   Psaty, Bruce M ^c   Macy, Elizabeth ^a   Bovill, Edwin G ^a   Cornell, Elaine S ^a   Kuller, Lewis H ^d   Tracy, Russell P ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

aged; blood coagulation factors; cardiovascular disease; fibrinopeptide A; prothrombin fragment 1 2

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A; BIOCHEMICAL MARKER; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; FIBRINOPEPTIDE A; GEMFIBROZIL; PROTHROMBIN; THROMBIN; TRIACYLGLYCEROL;

AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FIBRINOGEN BLOOD LEVEL; GERIATRIC PATIENT; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

EID: 0029782204     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.9.1163     Document Type: Article

References (55)

1. Nossel H, Yudelman J, Canfield R, Butler V, Spanondis K, Wilner G, Qureshi G. Measurement of fibrinopeptide A in human blood. J Clin Invest. 1974;54:43-53.
2. Soria J, Soria C, Mirshahi M, Samama M. Markers of fibrinogen derivatives used in clinical investigation. Semin Thromb Hemost. 1985;11:129-132.
3. Owen J. The utility of plasma fibrinopeptide assays. Thromb Haemost, 1989;62:807-810.
4. Gershlick A. Are there markers of the blood-vessel wall interaction and of thrombus formation that can be used clinically? Circulation. 1990;81(suppl I):I-28-I-34.
5. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 1991;65:153-159.
6. Eisenberg P, Sherman L, Schectman K, Perez J, Sobel B, Jaffe A. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation. 1985;71:912-918.
7. Pacchiarini L, Storti C, Zuchella M, Salerno JA, Grignani G, Fratino P. Fibrinopeptide A levels in patients with acute ischemic heart disease. Haemostasis, 1989;19:147-151.
8. Theroux P, Latour JG, Leger-Gauthier C, De Lara J. Fibrinopeptide A and platelet factor levels in unstable angina. Circulation. 1987;75:156-162.
9. Yudelman IM, Nossel HL, Kaplan KL, Hirsch J. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood. 1978;51:1189-1195.
10. Asakura H, Hifumi S, Jokaji H, Saito M. Kumabashiri I, Uotani C, Morishita E, Yamazaki M, Shibata K. Mizuhashi K, Mifune J, Matsuda T. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis. 1992;3:469-473.
11. De Buyzere M, Philippe J, Duprez G, Baele G, Clement DL. Coagulation system activation and increase of D-dimer levels in peripheral arterial occlusive disease. Am J Hematol. 1993;43:91-94.
12. Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. J Clin Invest. 1987;80:1527-1534.
13. Cadroy Y, Pierrejean D, Fontan B, Sie P, Boneu B. Influence of aging on the activity of the hemostatic system: prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. Nouv Rev Fr Hematol. 1992;34:43-46.
14. Hursting MJ, Stead AG, Crout FV, Horvath BZ, Moore BM. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem. 1993;39:683-686.
15. Rankinen T, Vaisanen S, Mercuri M, Rauramaa R. Apolipoprotein(a), fibrinopeptide A and carotid atherosclerosis in middle-aged men. Thromb Haemost. 1994;72:563-566.
16. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
17. Kirschstein W, Simianer S, Dempfle CE, Keller H, Stegaru B, Rentrop P, Heene DL. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA). Thromb Haemost. 1989;62:772-775.
18. Fuster V, Stein B, Ambrose J, Badimon L, Badimon J, Chesebro J. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation. 1990;82(suppl II):II-47-II-59.
19. Woolf N, Davies M. Interrelationship between atherosclerosis and thrombosis. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders Co; 1992:41-77.
20. Fuster V, Badimon L, Badimon J, Chesebro J. Pathogenesis of coronary artery disease and the acute coronary syndromes, part 1. N Engl J Med. 1992;326:242-250.
21. Fuster V, Badimon L, Badimon J, Chesebro J. Pathogenesis of coronary artery disease and the acute coronary syndromes, part 2. N Engl J Med. 1992;326:310-318.
22. Cortellaro M, Boschetti C, Confrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, della Volpe A, Polli E, and the PLAT Study Group. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients: principal results. Arterioscler Thromb. 1992;12:1063-1070.
23. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
24. Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S, Miller GJ, North WRS, Stirling Y, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
25. Kannel WB, Wolf PA, Castelli WP, D' Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA. 1987;258:1183-1186.
26. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation. 1991;83:836-844.
27. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341(8854):1165-1168.
28. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-59.
29. Tracy RP, Bovill EG. Thrombosis and cardiovascular risk in the elderly. Arch Pathol Lab Med. 1992;116:1307-1312.
30. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O'Leary DH, Psaty B, Rautaharju P, Tracy RP, Weiler PG, for the CHS Research Group. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-276.
31. Tell G, Fried L, Hermanson B, Manolio T, Newman A, Borhani N. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:358-366.
32. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;42:264-270.
33. O'Leary D, Polak J, Wolfson S, Bond M, Bommer W, Sheth S, Psaty B, Sharrett A, Manolio T, for CHS Investigators. Use of sonography to evaluate carotid atherosclerosis in the elderly: the Cardiovascular Health Study. Stroke. 1991;22:1155-1163.
34. Gardin J, Wong J, Bommer W, Klopfenstein H, Smith V, Tabatznik G, Siscovick D, Lobodzinski S, Anton-Culver H, Manolio T. Echocardiographic design of a multi-center investigation of free living elderly subjects. J Am Soc Echocardiogr. 1992;5:63-72.
35. Furberg CD, Manolio TA, Psaty BM, Bild DE, Borhani NO, Newman A, Tabatznik B, Rautaharju PM, for the Cardiovascular Health Study Research Group. Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Am J Cardiol. 1992;69:1329-1335.
36. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, Wolfson SK, for the Cardiovascular Health Study Collaborative Research Group. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study, Circulation. 1993;88:837-845.
37. Psaty BM, Kuller LH, Bild D, Burke GL, Kittner SJ, Mittelmark M, Price TR, Rautaharju PM, Robbins J. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1995;5:270-277.
38. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies: a classification system. Circulation. 1960;21:1160-1175.
39. Tracy R, Bovill E, Stump D, Lin T, Gomol T, Collen D, Mann K. Reduction of in vitro artifact during blood collection in TIMI II. Blood. 1988;78(suppl 1):376. Abstract.
40. Kockum C, Frebelius S. Rapid radioimmunoassay of human fibrinopeptide A: removal of cross-reacting fibrinogen with bentonite. Thromb Res. 1980;19:589-598.
41. Tracy R, Bovill E. Fibrinopeptide A. In: Beutler E, Lichtman M, Coller B, Kipps T, eds. Williams Hematology, 5th ed. New York, NY: McGraw-Hill, Publishing Co; 1995:L96-L97.
42. DeClerck P, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost. 1987;58:1024-1029.
43. Wong W, Eaton D, Berloui A, Fendly B, Hass P. A monoclonal-antibody - based enzyme-linked immunosorbent assay of lipoprotein(a). Clin Chem. 1990;36:192-197.
44. SPSS Inc. SPSS Version 6.1. Chicago, Ill: SPSS Inc; 1994.
45. Greenberg CS, Hursting MJ, Macik BG, Ortel TL, Kane WH, Moore BM. Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. Clin Chem. 1994;40:1962-1969.
46. Miller GJ, Bauer KA, Barzegar S, Foley AJ, Mitchell JP, Cooper JA, Rosenberg RD. The effects of quality and timing of venipuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost. 1995;73:82-86.
47. Liuzzo G, Biasucci L, Gallimore R, Grillo R, Rebuzzi A, Pepys M, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
48. Tracy R, Bovill E. Hemostasis and risk of ischemic heart disease: epidemiologic evidence with emphasis on the elderly. In: Califf R, Mark D, Wagner G, eds. Acute Coronary Care. 2nd ed. St Louis, Mo: CV Mosby Co; 1995:27-43.
49. Jang IK, Lassila R, Fuster V. Atherogenesis and inflammation. Eur Heart J. 1994;14(suppl K):2-6.
50. Tracy RP, Bovill EG, Fried LP, Heiss G, Lee MH, Polak JF, Psaty BM, Savage PJ. The distribution of coagulation factors VII, VIII and fibrinogen in adults over the age of 65 years: results from the Cardiovascular Health Study. Ann Epidemiol. 1992;2:509-519.
51. Cushman M, Yanez D, Psaty B, Fried L, Heiss G, Lee M, Polak J, Savage P, Tracy R. Correlates of fibrinogen and coagulation factors VII and VIII in the elderly: results from the Cardiovascular Health Study. Am J Epidemiol. 1996;143:665-676.
52. Wilkes HC, Meade TW, Barzegar S, Foley JA, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ. Gemfibrozil reduces plasma prothrombin fragment F1+2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost. 1992;67:503-506.
53. Tennant M, McGeachie J. Lipoprotein(a) and its role in occlusive vascular disease. Ann R Coll Surg Engl. 1993;75:3-7.
54. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118:956-963.
55. Ceriello A, Pirisi M, Giacomello R, Stel G, Falleti E, Motz E, Lizzio S, Gonano F, Bartoli E. Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost. 1994;71:593-595.